Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes

• Published in: Journal of hepatocellular carcinoma Vol. 7; pp. 107 - 116
• Main Authors: Campani, Claudia, Bensi, Carolina, Milani, Stefano, Galli, Andrea, Tarocchi, Mirko
• Format: Journal Article
• Language: English
• Published: Macclesfield Taylor & Francis Ltd 01.01.2020; Dove
• Subjects: Apoptosis; Biopsy; Cardiovascular diseases; Cell division; Cell growth; Cirrhosis; Clinical medicine; Cytokines; Diabetes; Diabetes mellitus; Fatty liver; Fibrosis; Hepatitis; Hepatocellular carcinoma; Insulin; Insulin-like growth factors; Kinases; Liver cancer; Liver cirrhosis; Liver diseases; Metabolic syndrome; Mortality; Obesity; Pathogenesis; Patients; Polymorphism; Population; Review; Risk assessment; Risk factors; Sarcopenia; Surgery; Surveillance; Transplantation; Tumor necrosis factor-TNF; Ultrasonic imaging; Weight control; United States > US
• ISSN: 2253-5969; 2253-5969
• DOI: 10.2147/JHC.S252506

Global prevalence of non-alcoholic fatty liver disease (NAFLD) has been growing in the last decades, especially in western countries, due to increased prevalence of diabetes, obesity or other components of metabolic syndrome. NAFLD recently became an important cause of hepatocellular carcinoma (HCC), even in non-cirrhotic patients. Patients with HCC-NAFLD are usually older, with more morbidities (especially cardiovascular diseases and metabolic disorders) and have advanced disease at the diagnosis due to the absence of surveillance, which is considered not cost-effective in patients without advanced fibrosis/cirrhosis, given the large prevalence of NAFLD in the general population. For these reasons, patients with HCC-NAFLD unlikely underwent curative treatments, and have been reported to have lower overall survival (OS) compared to individuals with HCC related to other aetiologies. However, this difference is not confirmed by data of patient subgroups who received curative treatment. In our review, we selected studies published over the past 8 years that analyse characteristics and outcomes of HCC-NAFLD patients who underwent surgery with the aim of identifying features that could predict outcomes and potential selection criteria. All the studies confirm that patients with HCC-NAFLD are older, with many comorbidities and that HCC occurs frequently even in non-cirrhotic livers. There is no agreement about intraoperative and perioperative complications. Regarding outcomes, all papers agree that patients with HCC in NAFLD who undergo surgery have a better OS compared to other aetiologies. Summarizing, surgery is a good curative option for patients with HCC-NAFLD, perhaps even better than transplantation in terms of OS. In this group of patients, it seems to be essential to evaluate cardio-pulmonary and general operative risk, in addition to the normal risk assessment related to liver function to avoid an underestimation, especially for patients without severe underlying fibrosis.